DelveInsight's“ Obesity Pipeline Insigh t 2025 ” report provides comprehensive insights about 80+ companies and 100+ pipeline ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...

Research shows promising results for a weekly injectable Parkinson's treatment that maintains consistent medication levels, ...

A once-a-week Parkinson’s injection could replace multiple daily pills, thanks to a new slow-release formulation developed by ...

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP ...

Researchers have developed a long-acting weekly injection that delivers steady doses of levodopa and carbidopa, potentially transforming care for Parkinson’s disease.

The FDA granted fast track designation to SAR446597, an intravitreal gene therapy for the treatment of geographic atrophy due to age-related macular degeneration, according to a press release from ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

A new weekly injection may soon transform how millions manage Parkinson’s disease. For over 8.5 million people living with ...

Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...